Patients (n = 157) | Control subjects (n = 142) | P | |
---|---|---|---|
Age (x ± σ years) | 64.8 ± 11.7 | 56.8 ± 9.4 | NS |
Sex . Men (%) | 121 (77 %) | 111 (78.2 %) | NS |
Women (%) | 36 (23 %) | 31 (21.8 %) | NS |
BMI (kg/m2) | 27.6 ± 4 | 23.3 ± 2.2 | NS |
Hypertension (%) | 88 | 0 | - |
Obesity (%) | 52 | 8.5 % | - |
Diabetes (%) | 64 | 0 | - |
Smoking (%) | 62.4 | 7 | - |
Family cardiac history (%) | 68 | 6 | - |
Personnel cardiac history (%) | 66 | 0 | - |
Postmenopausal women (%) | 100 | 82 | - |
Dyslipidemia (%) | 40 | 0 | - |
Sedentary (%) | 43 | 11 | - |
Alcohol (%) | 33 | 14 | - |
Glucose (x ± σ mmolL/) | 9.8 ± 4.2 | 5.40 ± 0.84 | <0.0001 |
TC (x ± σ mmol/L) | 5.70 ± 3.1 | 4.60 ± 2.6 | <0.001 |
HDL-C (x ± σ mmol/L) | 1.14 ± 0.22 | 1.30 ± 0.41 | NS |
LDL-C (x ± σ mmol/L) | 3.60 ± 2.16 | 2.80 ± 1.4 | <0.001 |
TG (x ± σ mmol/L) | 1.60 ± 0.9 | 1.24 ± 0.3 | NS |
ApoA1 (x ± σ. g/L) | 1.41 ± 0.62 | 1.80 ± 0.2 | <0.00001 |
ApoB (x ± σ. g/L) | 1.40 ± 0.81 | 0.70 ± 0.2 | <0.00001 |
Treatment: ACA-1 inhibitors (%) | 97 | 0 | - |
Statins (%) | 38 | 0 | - |
Beta-Blockers (%) | 33 | 0 | - |
Ca-Blockers (%) | 27 | 0 | - |
Diuretics (%) | 17 | 0 | - |